SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors

SCG Cell Therapy Pte Ltd announced that U.S. Food and Drug Administration has approved the Investigational New Drug application to initiate Phase 1/2 clinical trial for SCG142, a novel next-generation human papillomavirus E7-specific T-cell receptor-engineered T cell therapy for patients with HPV-associated solid tumors.